Premium
[P1–043]: ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG
Author(s) -
Lai Robert YK.,
Darpo Borje,
Dayal Satish,
Hall Nancy,
Chang MinKun,
Albala Bruce,
Ferry Jim,
Rege Bhaskar
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.110
Subject(s) - qt interval , medicine , moxifloxacin , placebo , assay sensitivity , dosing , crossover study , pharmacokinetics , pr interval , heart rate , confidence interval , pharmacology , anesthesia , cardiology , blood pressure , antibiotics , alternative medicine , pathology , microbiology and biotechnology , biology